Saturday, 31 October 2026European Markets

SIF HOLDING Stock Is 12% Up At Session Start Today

Loading stream...

(VIANEWS) - Shares of SIF HOLDING (AEX-Index: SIFG.AS) rose by a staggering 12.64% to €12.30 at 10:09 EST on Tuesday, following the last session's downward trend. AEX-Index is jumping 0.21% to €764.27, following the last session's upward trend. This seems, so far, a somewhat up trend exchanging session today.

About SIF HOLDING

Sif Holding N.V. manufactures and sells tubular steel foundations for offshore wind farms and metal structures, for the offshore industry in the Netherlands and internationally. The company operates through three segments: Wind, Marshalling, and Other. It engages in the production and delivery of monopiles, parts of metal structures, pipes, pipe structures, and components, as well as cans and cones, transition pieces, pin piles, jacket legs, and pile sleeves. The company rents logistical area and facilities; and delivers logistical services to the offshore wind industry. It serves energy companies, developers, and fabricators, as well as engineering, procurement, construction, and installation contractors. Sif Holding N.V. was founded in 1948 and is headquartered in Roermond, the Netherlands.

Earnings Per Share

As for profitability, SIF HOLDING has a trailing twelve months EPS of €0.28.

PE Ratio

SIF HOLDING has a trailing twelve months price to earnings ratio of 43.16. Meaning, the purchaser of the share is investing €43.16 for every euro of annual earnings.

Volume

Today's last reported volume for SIF HOLDING is 70947 which is 909.63% above its average volume of 7027.

More news about SIF HOLDING (SIFG.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com